Blackstone cures two ailments in one Moderna shot
Lending to a company is fine; taking a piece of its most promising investments is better. With higher costs of capital making spending decisions tougher for chief executives and buyout firms simultaneously struggling to invest stockpiles of cash, the deal between Blackstone and Moderna unveiled on Wednesday offers a crafty cure. The hard end of such bargains: surrendering value from potentially lu